The Xerion Team

Xerion’s management team has extensive commercial experience combined with pioneering nanotechnology expertise and support from world-leading oncologists.

Justin Stebbing

Professor Justin Stebbing – Chair

Professor of Cancer Medicine and Oncology, Consultant Oncologist, Imperial College and Imperial College Healthcare NHS Trust. Professor Stebbing specialises in a range of malignancies and their treatment with immunotherapy. He originally trained in medicine at Trinity College Oxford, where he gained a first class degree. After completion of junior doctor posts in Oxford, he undertook training and a residency programme at The Johns Hopkins Hospital in the US, returning to London to continue his career in oncology at The Royal Marsden and then St Bartholomew’s Hospitals. Professor Stebbing has published over 600 peer-reviewed papers in journals such as the Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine, as well as writing regularly for national newspapers and presenting new data on optimal cancer therapies at the major international conferences. He has an extensive clinical practice and links this to a wide number of translational research studies and immunotherapy trials.

Ian George

Dr Ian George – Chief Executive Officer

Dr George has a background in early stage healthcare companies and venture capital. He is CSO of New Wave Ventures, non-executive Director of several New Wave portfolio companies and Vice Chair of Cancer Research UK’s Pioneer Award. Previously he worked as a consultant at The Technology Partnership and prior to that at the Defence Science Technology Laboratory where he was responsible for the formation of several companies including P2i and Enigma Diagnostics which he co-founded in 2004.

Gareth Wakefield

Dr Gareth Wakefield – Chief Technical Officer

Following a BSc and PhD in Physics at the University of Bristol, Dr Wakefield spent five years at the University of Oxford researching novel applications of nanoparticles and quantum semiconductors. Dr Wakefield has over 15 years of experience of developing nanoparticle technology in University of Oxford spin out companies, Oxonica and Oxford Advanced Surfaces. Dr Wakefield co-founded Oxonica in 1999, managing the technical team through development of Optisol sunscreen additives and Envirox diesel catalysts and through to Oxonica’s successful AIM listing in summer 2005.

Megan Adiar

Ms Megan Adair – Quality Manager

Megan has a MChem in Chemistry from the University of Bradford and has spent nine years in industry working for Oxford Advanced Surfaces and Unilever in scientific development, quality control and analytical development. Megan has been Quality Manager at Xerion Healthcare since February 2017.

X Icon